Historical overview, development and new approaches in design of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Part I

Abstract

Cardiovascular diseases (CVDs) are disorders of the heart and blood vessels, and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. Four out of five CVD deaths are due to heart attacks and strokes. Individuals at risk of CVD may demonstrate elevated blood pressure, glucose, and lipids as well as over

Cardiovascular Calcium Channel Blockers: Historical Overview, Development and New Approaches in Design

“…All the new nonpeptide angiotensin II antagonists that have been designed contain a biphenyl fragment bearing an acidic moiety (i.e., a tetrazole, carboxylic‐, or sulphonamidocarboxyl group), linked to a heteroaromatic or acyclic system by a methylene group. Almost all chemical manipulations of the fundamental skeleton of sartans have focused on the substitution of the imidazole ring of losartan with different heteroaromatic groups or acyclic structures .…”